Rationale Psychoactive-substituted phenethylamines 2,5-dimethoxy-4-chlorophenethylamine (2C-C); 2,5-dimethoxy-4-methylphenethylamine (2C-D); 2,5-dimethoxy-4-eth ylphe nethy l amine (2 C-E); 2, 5-dime th oxy -4-i o d o p h e n e t h y l a m i n e ( 2 C -I ) ; 2 , 5 -d i m e t h o x y -4 -ethylthiophenethylamine (2C-T-2); and 2,5-dimethoxy-4-chloroamphetamine (DOC) are used recreationally and may have deleterious side effects. Objectives This study compares the behavioral effects and the mechanisms of action of these substituted phenethylamines with those of hallucinogens and a stimulant.
Introduction
Synthetic "designer" hallucinogens are psychoactive compounds derived from phenalkylamines such as mescaline and amphetamine, from tryptamines such as N ,N ,-dimethyltryptamine (DMT), or ergolines such as lysergic acid diethylamide (LSD) (Nichols 2004) . These psychoactive drugs do not produce any clear withdrawal syndrome (Shulgin and Shulgin 1991) , but psychosis in predisposed individuals following LSD ingestion has occurred (reviewed in Cohen 1967; Nichols 2004) . The United States Drug Enforcement Agency has categorized some hallucinogenic compounds, including LSD, DMT, and substituted phenethylamines 2,5-dimethoxy-4-chlorophenethylamine (2C-C); 2,5-dimethoxy-4-methylphenethylamine (2C-D); 2,5-dimethoxy-4-ethylphenethylamine (2C-E); and 2,5-dimethoxy-4-iodophenethylamine (2C-I); 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) ( Fig. 1) , as schedule 1 substances, a category having abuse liability and no recognized therapeutic uses (DEA 2013). 2,5-Dimethoxy-4-chloroamphetamine (DOC) is regulated by the Federal Analog Act. The synthesis and psychoactive properties of the phenethylamines in humans have been described (Shulgin and Shulgin 1991) .
The reported effects of these compounds are dosedependent, with a combination of stimulant and hallucinogenic effects (reviewed in Dean et al. 2013) . Generally, stimulation and increased visual, auditory, and tactile sensation are seen with low doses; hallucinations with moderate doses; and unpleasant hallucinations, tachycardia, hypertension, and excited delirium with higher doses (Dean et al. 2013) . While there is a paucity of clinical data, some case reports of adverse side effects include stroke and quadriplegia following ingestion of 2C-I with 3,4-methylenedioxyamphetamine (Drees et al. 2009) , and seizures and rhabdomyolysis following ingestion of DOC, MDMA, and ethanol (Ovaska et al. 2008) .
Although there is agreement that the neuronal serotonergic system is involved in the discriminative stimulus effects of hallucinogenic compounds (Glennon et al. 1984; Winter 2009) , debate continues regarding which receptor subtypes are involved and whether the compounds are agonists, partial agonists, or antagonists (reviewed in Halberstadt and Geyer 2011; Nichols 2004) . Possible biochemical targets of these compounds have been investigated in several systems (Berg et al. 1998; KurraschOrbaugh et al. 2003; Moya et al. 2007 ). Using antagonists with differential affinity for 5-HT 2A and 5-HT 2C receptors in rats trained to discriminate LSD and 2,5-dimethoxy-4-methylamphetamine (DOM) from water, Fiorella et al. (1995) found that affinities of antagonists at 5-HT 2A , but not 5-HT 2C , receptors correlated with IC 50 values for blocking LSD and DOM behavioral effects. 5-HT 2A receptor antagonists also decreased rhesus monkeys' responding to the phenethylamines DOM and 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) (Li et al. 2010) . Thus, the stimulus effects of some substituted ergolines and phenethylamines may be elicited by 5-HT 2A receptor agonist activity. 2C-C, 2C-E, and 2C-I partially stimulated guanosine 5′-O-[gamma-thio]triphosphate (GTPγS) binding in cortical membranes, an effect blocked by methiothepin, an antagonist for 5-HT 1 , 6 ,& 7 receptors ). In rat brain synaptosomes, 2C-C, 2C-E, and 2C-I inhibited serotonin and norepinephrine uptake at mid-micromolar concentrations but had no effect on dopamine uptake or neurotransmitter release via the transporters .
The goal of this study was to assess the behavioral effects and mechanisms of action of these substituted phenethylamines. First, drug-induced locomotor changes were characterized in mice to estimate the effective dose range and time course of the behavioral effects. Next, the ability of these compounds to produce discriminative stimulus effects similar to those of a range of known drugs of abuse was tested in rats. Because phenethylamines can produce either psychostimulant or hallucinogenic effects, a number of compounds with a range of stimulant and/or hallucinogenic effects were used to screen for psychoactive effects. In addition, the ability of these compounds to bind to and activate pharmacological targets of known abused drugs was examined to confirm and extend the biochemical data available for these substituted phenethylamines. The 4-substituents on the phenyl ring can differentially influence the biochemical activity of the phenethylamines (Nichols 1986b) . 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors are primary pharmacological targets for hallucinogens such as DMT and LSD, and the methylated phenethylamine, amphetamine, exerts its initial effects via the dopamine, serotonin, and norepinephrine transporters, leading to effects at neurotransmitter (dopamine) receptors. For these reasons, the drug effects on these systems were characterized. 
Materials and methods

Subjects
Locomotor activity
The study was conducted using 40 Digiscan (model RXYZCM, Omnitech Electronics, Columbus, OH, USA) locomotor activity testing chambers (40.5×40.5×30.5 cm) housed in sets of two, within sound-attenuating chambers as previously described (Gatch et al. 2011) . Separate groups of eight mice were injected intraperitoneally with either vehicle (0.9 % saline), 2C-C (1, 3, 10, 30, and 100 mg/kg), 2C-D (1, 3, 10, and 30 mg/kg), 2C-E (0.03, 0.1, 0.3, 1, 3, 10, and 30 mg/kg), 2C-I (0.3, 1, 3, 10, and 30 mg/kg), 2C-T-2 (0.1, 0.3, 1, 3, and 10 mg/kg), or DOC (0.1, 0.3, 1, 3, and 10 mg/kg), immediately prior to locomotor activity testing. In all studies, horizontal activity (interruption of photocell beams) was measured for 8 h within 10-min periods, beginning at 0800 (2 h after lights on).
Discrimination procedures
Standard behavior-testing chambers (Coulbourn Instruments, Allentown, PA, USA) were connected to IBM PC compatible computers via LVB interfaces (Med Associates, East Fairfield, VT, USA). The computers were programmed in MED-PC IV (Med Associates) for the operation of the chambers and collection of data. Using a two-lever choice methodology, separate groups comprising 15 to 32 rats were trained to discriminate one of the five compounds from saline: METH (1 mg/kg), MDMA (1.5 mg/ kg), LSD (0.1 mg/kg), DOM (0.5 mg/kg), and DMT (5 mg/kg) as previously described (Gatch et al. 2009; Gatch et al. 2011 ). The rats were injected i.p. with either saline or drug and then placed in the operant chambers, where food (45 mg of food pellets; Bio-Serve, Frenchtown, NJ, USA) was available under a fixed-ratio 10 schedule of reinforcement. Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Pretreatment times were 5 min for DMT, 10 min for METH, 15 min for LSD and MDMA, and 30 min for DOM.
The substitution test sessions lasted for a maximum of 20 min. In contrast with the training sessions, both levers were active, such that ten consecutive responses on either lever led to reinforcement. Data were collected until 20 reinforcers were obtained, or for a maximum of 20 min. 2C-C, 2C-D, 2C-E, 2C-I, 2C-T-2, or DOC were tested for substitution in subsets of six rats from each training drug group. Doses of these compounds were presented incrementally in separate sessions, using a repeated measures design (i.e., each of the six rats was tested at all doses). All the compounds were tested 15 min after i.p. injection, based on the earliest time a locomotor effect was observed. DOC and 2C-D were also tested 60 and 70 min, respectively, after injection in separate groups of rats to investigate whether stimulus control was different during the stimulant phase. (Eshleman et al. 2013; Gatch et al. 2011; Knight et al. 2004; Kurrasch-Orbaugh et al. 2003) .
5-HT receptors
Human dopamine, serotonin, and norepinephrine transporters: binding, uptake, and release ]neurotransmitter uptake, and neurotransmitter release assays were conducted as previously described (Eshleman et al. 1999; Eshleman et al. 2013; Gatch et al. 2011) . The HEK cells expressing recombinant human dopamine (hDAT), human serotonin (hSERT), or human norepinephrine (hNET) were used. (Toll et al. 1998 ).
Drugs
For behavioral assays, all drugs were dissolved in 0.9 % saline. Hydrochloride salts of 2C-C, 2C-D, 2C-E, 2C-I, 2C-T-2, DOC, (−)-cocaine, S (+)-METH, (±) and (+)-3,4-methylenedioxymethamphetamine (MDMA), and (−) 
Data analysis
Locomotor activity data were expressed as the mean number of photocell counts in the horizontal plane during each 10-min testing period. A 30-min period, beginning when the maximal stimulation of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values from the ascending linear portion of the dose-response curve. A one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against saline control using single degree of freedom F tests. Drug discrimination data were expressed as the mean percentage of training-drugappropriate responses occurring in each substitution test. The response rates were expressed as the number of responses made, divided by the total session time. Percent training drugappropriate responding was not calculated if a rat failed to complete at least ten responses on one of the levers, and doses for which fewer than three rats met this criterion were not considered in the discrimination data analysis. Full substitution was defined as ≥80 % drug-appropriate responding and not statistically different from the training drug, and partial substitution as ≥40 and <80 % drug-appropriate responding and not statistically different from the training drug. The ED 50 values were calculated by fitting straight lines to the doseresponse data for each compound by means of TableCurve 2D (Jandel Scientific, San Rafael, CA, USA). The response rate data were analyzed by one-way repeated measures ANOVA. The effects of the individual doses were compared to the appropriate control value using single degree of freedom F tests. The criterion for significance was set at p <0.05.
For binding and functional assays, IC 50 or EC 50 values were calculated with GraphPad Prism. The binding IC 50 values were converted to K i values using the Cheng-Prusoff correction (Cheng and Prusoff 1973) ; the K d values used are listed in (Eshleman et al. 2013) . Fractional release was defined as the amount of radioactivity in a fraction divided by the total radioactivity remaining in the sample. For serotonin receptor functional assays, the drug effect each day was normalized to maximal serotonin effect. One-way ANOVAs were conducted using the logarithms of K i , IC 50 , or EC 50 values followed by Tukey's post hoc analysis. For release assays, area under the curve (AUC) was calculated using GraphPad Prism. The criterion for significance was set at p <0.05. Figure 2 shows the time course data for the test compounds. Because of the large amount of data, only doses which produced peak depressant or stimulant effects are shown, along with vehicle data for comparison. Treatment with 2C-C resulted in time-and dose-dependent depression of locomotor activity following 30 and 100 mg/kg (F (5,41) =32.94, p < 0.001); these effects occurred within 10 min following injection and lasted 30 to 120 min. Convulsions were observed in 2/8 mice, and tremors in 6/8 mice at 30 min following 100 mg/ kg 2C-C. Lethality occurred in 1/8 mice within 120 min following 100 mg/kg. Treatment with 2C-I resulted in timeand dose-dependent depression of locomotor activity following 3-30 mg/kg (F (5,42) =20.90, p <0.001); depressant effects occurred within 10 min following injection and lasted 30-60 min ( Table 1 shows the summary data for the drug discrimination studies. 2C-C fully substituted for the discriminative stimulus effects of DOM (ED 50 =0.95±0.09 mg/kg) and MDMA (ED 50 = 1.48±0.15 mg/kg). 2C-C (5 mg/kg) produced a maximum of 75 % drug-appropriate responding in both DMT-and LSDtrained rats, whereas 2C-C (10 mg/kg) produced minimal drugappropriate responding in METH-trained rats. 2C-C decreased response rates following 2.5 mg/kg in MDMA-trained rats (F (4, The adverse effects were observed following 25 mg/kg 2C-C, including reddening of the extremities (3/3 rats) and salivation (1/ 3 rats), and this dose was not tested in DMT-or LSD-trained rats. 2C-D was tested at two time points, 15 and 70 min, which corresponded with peak depressant and peak stimulant locomotor activity effects, respectively. At 15 min after administration, 2C-D fully substituted for the discriminative stimulus effects of DMT (ED 50 =3.14±0.15 mg/kg), DOM (ED 50 =0.77±0.10 mg/kg), and LSD (ED 50 =0.71±0.12 mg/ kg). 2C-D (2.5 mg/kg) produced 61 % drug-appropriate responding in MDMA-trained rats, and 10 mg/kg produced 15 % METH-appropriate responding (Table 1 ). The response rate was decreased following 1 and 2.5 mg/kg in DOM- 2C-E fully substituted for the discriminative stimulus effects of DMT (ED 50 =0.95±0.20 mg/kg), DOM (ED 50 =0.84± 0.08 mg/kg), LSD (ED 50 =0.62±0.10 mg/kg), and MDMA (ED 50 =2.48±0.10 mg/kg) but produced minimal METHappropriate responding. The response rate was decreased following 2.5, 5, and 10 mg/kg in MDMA-trained rats (F (9,45) = 10.25, p <0.001), and 5 and 25 mg/kg in METH-trained rats (F (10,50) =4.01, p <0.001). Loss of muscle tone was observed at 10 mg/kg in MDMA-trained rats, and 25 mg/kg 2C-E completely suppressed responding.
Results
Locomotor activity
2C-I fully substituted for the discriminative stimulus effects of DMT (ED 50 =0.68±0.11 mg/kg) and LSD (ED 50 =1.66 mg/ kg±0.12). In MDMA-trained rats, 2.5-10 mg/kg 2C-I produced a maximal 65 % drug-appropriate responding, and 1 mg/kg 2C-I produced only 38 % drug-appropriate responding in METH-trained rats (Table 1 ). The response rate was decreased with doses of 2.5-10 mg/kg 2C-I in MDMAtrained rats (F (4,20) =3.66, p =0.022) and with 1 and 5 mg/kg in METH-trained rats (F (4,20) =5.08, p =0.005).
2C-T-2 produced 73 % drug-appropriate responding following 2.5 mg/kg in DMT-trained rats. A 10 mg/kg dose of 2C-T-2 elicited hind limb paralysis, salivation, and loss of muscle tone, and was not tested further. 2C-T-2 failed to substitute for LSD, MDMA, or (+)-METH. 2C-T-2 substantially decreased response rates following 2.5 and 5 mg/kg in rats trained to DMT (F (5,25) = 6.66, p <0.001), LSD (F (4,20) =4.60, p= 0.008), MDMA (F (3,15) =3.46, p =0.043), and (+)-METH (F (3,15) =14.75, p <0.001). In each case, 5/6 rats failed to complete the first fixed ratio at the highest dose tested. Decreased muscle tone was observed in 3/6 rats following 5 mg/kg 2C-T-2 in LSD-trained rats.
DOC was tested at two time points, 15 and 60 min, which corresponded with the peak depressant and peak stimulant locomotor activity effects, respectively. At 15 min following administration, DOC fully substituted for the discriminative stimulus effects of DOM (ED 50 =0.13±0.16 mg/kg) and LSD (ED 50 = 0.39 ± 0.33 mg/kg). DOC produced 65 % DMTappropriate responding following 1 mg/kg, and less than 50 % drug-appropriate responding in MDMA-trained and METH-trained rats. The response rate was decreased following 2.5 mg/kg DOC in rats trained to LSD (F (7, 35) =3.86, p = 0.003), MDMA (F (5,25) =3.81, p =0.011), and METH (F (5, 25) =3.86, p =0.010). With 2.5 mg/kg DOC, substantial rate suppression was observed, such that 4/6 or 5/6 rats tested in each case failed to respond, and decreased muscle tone was observed in 12/24 rats. At 60 min, DOC fully substituted for the discriminative stimulus effects of DMT (ED 50 =0.61±0.19 mg/ kg), DOM (ED 50 =0.26±0.19 mg/kg), and LSD (ED 50 =0.23± 0.10 mg/kg). In MDMA-trained rats, DOC produced 60 % drug-appropriate responding following 1 mg/kg, and no drugappropriate responding at any dose in METH-trained rats. Doses of 1 mg/kg and higher decreased the response rates in rats trained to DMT (F (5, 25) =3.66, p =0.013), LSD (F (5,25) = 2.96, p =0.031), MDMA (F (6,30) =3.96, p =0.005), and METH (F (6,30) =4.07, p =0.004). Substantial rate suppression and failure to complete the first fixed ratio were observed following The experiments were conducted as described in the "Materials and methods" section. Data presented are means ± SEM. a Agonist assay. Basal activity is subtracted, and the data are normalized to the maximal stimulation by serotonin on each experimental day. n =3-5 except n =2 for 2C-I. b Antagonist assay. Nonspecific release, measured in the presence of 30 μM ketanserin, is subtracted from all data, and the data are normalized to the maximal release stimulated by serotonin. n =3-4 2.5 mg/kg DOC in MDMA-trained rats (4/6 rats) and 5 mg/kg in METH-trained rats (5/6 rats). 2C-I and 2C-T-2 had similar low micromolar potencies, and 2C-T-2 was more potent than MDMA and METH (p values <0.001). The four other phenethylamines had minimal efficacy (<25 %). 2C-I and 2C-T-2 had similar efficacies to serotonin and LSD, and 2C-I had higher efficacy than DOM, MDMA, and METH (p <0.05).
In HEK-h5-HT 2A cells, the phenethylamines were tested for their affinity for the [ (IP-1 assay) ). The binding affinities of the drugs were significantly different (p <0.0001, oneway ANOVA, Table 2 ). LSD had higher affinity than all other tested compounds (p values <0.001). The phenethylamines had high affinities, and their K i values did not differ from each other or from serotonin or DOM (p >0.05), and were higher than DMT, MDMA, and METH (p values <0.001).
In the 5-HT 2A [
3 H]AA release assay, 2C-C, 2C-D, 2C-E, 2C-T-2, DOC, LSD, and 5-HT were agonists with similar efficacies (p =0.26, one-way ANOVA, Table 2 ), while potencies differed significantly (p <0.0001, one-way ANOVA). LSD and serotonin had potencies in the low nanomolar range, with LSD having higher potency (p <0.01). 2C-T-2, 2C-E, and DOC were very potent with EC 50 values that did not differ from serotonin and LSD. 2C-T-2, 2C-C, 2C-E, DOC, LSD, and serotonin were more potent than 2C-D and DMT (p values <0.05 to 0.001). In contrast, 2C-I minimally stimulated the release (Fig. 3a) , and no EC 50 was determined. This finding was unexpected, since 2C-I substituted for the discriminative effects of LSD and DMT, which stimulated [ 3 H]AA release (Table 2 and Fig. 3a) . 2C-I fully inhibited serotonin-stimulated [ 3 H]AA release with low potency, similar to ketanserin (p >0.05, two-tailed t test, Fig. 3b ). To confirm that the same compound was used in behavioral and biochemical assays, an aliquot of 2C-I from the behavioral assays was tested and confirmed 2C-I antagonism of serotonin-mediated [ 3 H]AA release. In the 5-HT 2A IP-1 functional assay, all the compounds tested were agonists (except METH with no measurable efficacy), with significantly different potencies (p <0.001, one-way ANOVA, Table 2 , Fig. 4a ). LSD had higher potency (p values <0.001), while MDMA had lower potency (p values <0.001) than all other compounds. 2C-I and 2-C-T-2 were the most potent phenethylamines. 2C-I had higher potency than serotonin, 2C-D, and 2C-E (p values <0.05 to 0.001). 2C-T-2 had higher potency than serotonin, DOM, 2C-D, and 2C-E (p values <0.05 to 0.001). 2C-C, 2C-D, 2C-E, DOC, DOM, and serotonin had similar potencies. Efficacies differed significantly (p <0.0001, one-way ANOVA). 2C-E had higher efficacy than LSD, 2C-I, and 2C-T-2 (p values <0.05). 2C-C, 2C-D, 2C-I, 2C-T-2, DOC, serotonin, LSD, and DOM had similar efficacies. DMT and MDMA had similar efficacy that was lower than all the other compounds (p values <0.01).
In HEK-h5-HT 2C cells, the phenethylamines were tested for their affinities for the [ For test compounds, n =2 (when >10 μM) to 7. Data are expressed as mean ± SEM. The standard compounds were, for purposes of comparison, cocaine for the binding and uptake assays, Values from Gatch et al. 2011 there were significant differences in affinities (p <0.0001, oneway ANOVA). 2C-C, 2C-D, 2C-E, 2C-I, 2C-T-2, DOC, serotonin, and LSD had similar, low nanomolar affinities (Table 2) . DOM had lower affinity than serotonin and LSD (p <0.01) but was similar to the phenethylamines. DMT had similar affinity to DOM. MDMA and METH had similar affinities which were lower than all the other compounds (p <0.001).
All compounds were 5-HT 2C agonists, activating the phospholipase C-inositol phosphate cascade, with significant differences in potencies (p <0.001, one-way ANOVA, Table 2 , Fig. 4b ). The highest potency drugs were LSD, serotonin, 2C-I, 2C-T-2, and DOM. 2C-I was more potent than 2C-D, DMT, MDMA, and METH (p values <0.01). 2C-T-2 was more potent than DMT, MDMA, and METH (p values <0.001). 2C-C, 2C-D, 2C-E, and DOC had similar low-to mid-nanomolar potencies and were less potent than serotonin (p values <0.05) and LSD (except DOC). DMT, MDMA, and METH had very low potencies. Efficacies did not differ (p =0.28, one-way ANOVA).
In vitro pharmacology: interaction with hDAT, hSERT, and hNET, and dopamine receptors
In the transporter assays, the phenethylamines had no measurable or very low affinity for hDAT and hNET in the binding assays, and very low potency (at least micromolar) in the (Table 3) . Only 2C-I had measurable affinity (high nanomolar) for hSERT and very low potency in the [ 3 H]serotonin uptake assay. In the release assays, the compounds had no releasing efficacy, while METH elicited robust release in all the cell lines. The phenethylamines also had no measurable affinity for the dopamine D1, D2, and D3 receptors (data not shown). Thus, the substituted phenethylamines have minimal interaction with hDAT, hNET, and dopamine receptors, and very low potency at hSERT.
Discussion
The discriminative stimulus effects of six substituted phenethylamines were tested in separate groups of rats trained to discriminate DMT, DOM, LSD, MDMA, or METH from saline. Previously, we reported that these training compounds produced nonidentical patterns of cross-substitution: LSD fully substituted for all training compounds except METH; MDMA fully substituted for all compounds except partial substitution for LSD; DOM substituted fully for DMT and LSD, partially for MDMA, but not for METH; DMT substituted fully for DOM, partially for LSD and MDMA, but not for METH; while METH only substituted for MDMA (Gatch et al. 2009 ).
In the current study, five of the six phenethylamines produced full substitution to at least one of the three prototypic hallucinogens, LSD (ergoline), DMT (tryptamine), and DOM (phenalkylamine). In LSD-trained rats, 2C-D, 2C-E, 2C-I, and DOC fully substituted (≥80 % DAR), whereas 2C-C produced 75 % LSD-appropriate responding. The pattern of substitution for DMT-trained rats was similar, with the addition of partial substitution by 2C-T-2. The four compounds tested in DOMtrained rats (2C-C, 2C-D, 2C-E, and DOC) all fully substituted, suggesting that these phenethylamines have very similar discriminative stimuli to DOM, consistent with their structural similarities. In contrast, 2C-T-2 partially substituted only for DMT, indicating that it does not share discriminative stimulus effects with most serotonergic hallucinogens or with psychostimulants.
For the MDMA-trained rats, 2C-C and 2C-E fully substituted, 2C-D, 2C-I, and DOC produced 60 to 65 % MDMAappropriate responding, but DOC produced only 44 %. These findings are similar to those of earlier studies in which MDMA, an entactogen that induces feelings of empathy and emotional closeness to others (Nichols 1986a) , did not consistently crosssubstitute for the classic serotonergic hallucinogens (Baker et al. 1995; Gatch et al. 2009; Oberlender and Nichols 1988; Schechter 1998) .
In agreement with very low potencies of 2C-C, 2C-E, and 2C-I for inhibition of uptake and minimal stimulation of release in rat brain synaptosomes ), the phenethylamines minimally substituted for METH, consistent with their low to negligible affinity and potency at the transporters. This suggests that the compounds have minimal psychostimulant properties and agrees with the general depression of locomotor activity by other hallucinogens (Krebs and Geyer 1994; Krebs-Thomson et al. 1998) , although lower doses of 2C-D, 2C-E, and DOC had a delayed stimulant activity.
Many studies have demonstrated the involvement of G protein-coupled 5-HT 2 receptors in the actions of hallucinogenic drugs including LSD, DOM, DOI, and 2,5-dimethoxy-4-bromophenethylamine (2C-B) (Egan et al. 2000; Fantegrossi et al. 2008; Glennon et al. 1984; Kurrasch-Orbaugh et al. 2003; Titeler et al. 1988 ). More specifically, 5-HT 2A/2C receptors, which have high sequence homology and similarity in second messenger signaling, are important targets of hallucinogenic compounds (reviewed in Fantegrossi et al. 2008; Halberstadt and Geyer 2011; Nichols 2004; Winter 2009 ). Both 5-HT 2A/2C receptors activate phospholipase A 2 via Gα 12/13 , liberating AA from membrane phospholipids (reviewed in Raymond et al. 2001) and activate phospholipase C via G q/11 , generating the second messengers inositol triphosphate and diacylglycerol with subsequent release of intracellular stores of calcium and protein kinase C activation (Backstrom et al. 1999) . Among the training compounds, LSD and DOM were full agonists at the 5-HT 2A / 2C receptors, although in rat brain membranes and NIH3T3-5HT 2A cells, these compounds are partial agonists (Kurrasch-Orbaugh et al. 2003; Sanders-Bush et al. 1988 ). In contrast, at the 5-HT 2A receptor, DMT and MDMA were very low potency partial agonists, and METH had no efficacy. On the other hand, at the 5-HT 2C receptor, DMT and MDMA were low to very low potency full agonists, and METH was a very low potency partial agonist. Activation of 5-HT 1A receptors may not play a role in the discriminative stimulus (Nichols 2004) . While LSD was a very potent full 5-HT 1A agonist, all the other psychoactive exogenous compounds tested had potencies in the micromolar range, and only 2C-I and 2C-T-2 had partial to full efficacy among the phenethylamines. These results partly agree with the partial stimulation of GTPγS binding in brain preparations by 2C-C, 2C-E, and 2C-I .
In CHO cells expressing the 5-HT 2A or 5-HT 2C receptors, 2C-D, 2C-I, and 2C-B were partial, low potency agonists for the phospholipase C or A2 pathways (Moya et al. 2007 ). Herein, 2C-C and DOC had similar affinities for 5-HT 2A/2C receptors, and each was a full agonist with similar potencies at both receptors, similar to LSD and DOM. 2C-D had higher affinity for, and was a full agonist with slightly higher potency at, the 5-HT 2C compared to the 5-HT 2A receptor. 2C-E had similar affinity for the 5-HT 2A/2C receptors and was a partial agonist in the 5-HT 2A AA assay, but a full agonist in stimulating the inositol phosphate pathway by both 5-HT 2A/2C receptors. Although 2C-T-2 substituted partially only for DMT, it was a full high potency agonist at the 5-HT 2A/2C receptors, similar to LSD. A structurally similar compound, 2,5-dimethoxy-4-propylthiophenethylamine (2C-T-7), partially substitutes for LSD and serves as a discriminative stimulus, an effect blocked by a 5-HT 2A antagonist (Fantegrossi et al. 2005 ). 2C-T-2 has been sold on the internet and in Europe (de Boer and Bosman 2004) , and anecdotal evidence (Erowid.com) suggests that it is psychoactive.
In contrast, 2C-I had differential effect on 5-HT 2A -mediated pathways. 2C-I had high affinity for both 5-HT 2A/2C receptors, consistent with K i and K d values obtained using stable HEK-5HT 2A cells (Parrish et al. 2005 ) and [ 125 I]2C-I in rat frontal cortex, which did not discriminate between 5-HT 2A and 5-HT 2C receptors (Johnson et al. 1990 ). 2C-I fully antagonized serotonin's activation of the phospholipase A2/[ 3 H]AA release pathway. However, 2C-I was a full agonist, with efficacy similar to LSD, in 5-HT 2A/2C receptor-mediated IP-1 formation. Because 2C-I fully substituted for DMT and LSD, and stimulated phospholipase C, but not phospholipase A2 pathway, the former pathway may be more significant in 2C-I drug discrimination. Similarly, Parrish et al. (2005) observed 2C-I to be a partial agonist with high potency at the phospholipase C pathway. Consistent with the possible importance of the phospholipase C pathway, a conformationally restricted 2C-B analog ((R )-4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methyl-amine) was equipotent to LSD in rats trained to discriminate LSD from saline and was 65-fold more potent at stimulating inositol phosphate turnover than AA release, although the authors suggested that preferential stimulation of this pathway may indicate lower psychoactivity (McLean et al. 2006) . Using a phospholipase C inhibitor, Schindler et al. (2013) found that phospholipase C activation is necessary for DOI-elicited head bobs in mice, while LSD-elicited head bobs are independent of this pathway, suggesting distinct pathways for these structurally dissimilar hallucinogens. A caveat to the possible relative contribution of 5-HT 2A pathways to hallucinogenic activity is the abundant evidence that the cell types used to express serotonin receptors, as well as the second messenger systems characterized, have impact on whether a drug is an agonist, partial agonist, or antagonist (AcunaCastillo et al. 2002; Kurrasch-Orbaugh et al. 2003; Moya et al. 2007; Rabin et al. 2002; Villalobos et al. 2004) .
To summarize, the relationship between drug substitution, mechanism of action, and potential for abuse for these drugs is not uniform. 2C-C, 2C-D, 2C-E, and DOC fully substituted for the discriminative stimuli of the hallucinogenic phenethylamine DOM and fully to partially substituted for LSD, and have agonist profiles similar to those of DOM and LSD at the 5-HT 2A/2C receptors. In contrast, 2C-I substituted fully for hallucinogenic compounds, but its pharmacology is more complex, as it fully stimulated the 5-HT 2A/2C receptor phospholipase C pathways but inhibited the 5-HT 2A receptor phospholipase A2 pathway, as discussed above. Finally, 2C-T-2 was a full, high potency agonist at 5-HT 2A/2C receptors but produced appreciable drug-appropriate responding for only one training drug (DMT). Overall, there was not a good correlation between potencies and efficacies in drug discrimination assays and binding/functional assays, suggesting that complex mechanisms or additional receptor systems may modulate behavior.
These behavioral and biochemical findings, together with ongoing reports of use on the internet (Erowid.com), suggest that the compounds have high abuse liability. In addition, the adverse effects we observed in rat and mouse behavioral assays included tremor, muscle spasms, hind limb paralysis, and lethality, and indicate toxicity at higher doses. Recent reports of seizures and serotonin syndrome following 2C-I ingestion (Bosak et al. 2013) , fatal toxic leukoencephalopathy and acute kidney failure following 2C-E ingestions (Sacks et al. 2012; Van Vrancken et al. 2013) , and seizures and rhabdomyolysis following DOC and MDMA co-ingestion (Ovaska et al. 2008) suggest consumption of these phenethylamines carries significant health risk.
